文献速递慢性肾脏病血液净化与透析

每周一次司美格鲁肽对SUSTAIN 6试验中不同KDIGO风险分层的肾脏结局影响

Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 Trial.
PubMed 文献 · Kidney Int Rep · 2024-05-22

SUSTAIN 6试验的事后分析按基线KDIGO风险分层(低1596例、中831例、高445例、极高366例)评估每周一次司美格鲁肽对比安慰剂的肾脏复合终点及KDIGO风险类别变化。结果显示各风险层治疗效果一致(P交互=0.28),司美格鲁肽组更易转为更低KDIGO风险类别(OR 1.69,95%CI 1.32-2.16)且更少转为更高类别(OR 0.71,95%CI 0.59-0.86)。

要点

  • 司美格鲁肽降低肾脏复合终点风险在各KDIGO风险层一致(P交互=0.28)。
  • 司美格鲁肽组更易转为更低KDIGO风险类别(OR 1.69,95%CI 1.32-2.16)。
  • 司美格鲁肽组更少转为更高KDIGO风险类别(OR 0.71,95%CI 0.59-0.86)。

核心结论

  • 每周一次司美格鲁肽对比安慰剂降低肾脏疾病终点风险并改善KDIGO风险类别,且不依赖基线KDIGO风险分层。

研究设计与样本

  • SUSTAIN 6(NCT01720446)的事后分析,纳入2型糖尿病合并确诊心血管疾病或高心血管风险者,接受每周一次司美格鲁肽或安慰剂治疗。
  • 按基线KDIGO风险类别分层:低风险1596例、中风险831例、高风险445例、极高风险366例。
  • 分析从基线至2年的肾脏疾病复合终点(大量白蛋白尿、血清肌酐翻倍且eGFR<45 ml/min/1.73 m2、肾脏替代治疗或肾脏疾病死亡)。

主要发现

  • 肾脏疾病复合终点的治疗效果在各KDIGO类别间一致:低风险HR 0.35(95%CI 0.07-1.72),中风险HR 0.42(95%CI 0.25-0.72),高风险HR 0.87(95%CI 0.45-1.71),极高风险HR 0.72(95%CI 0.42-1.23);P交互=0.28。
  • 司美格鲁肽组对比安慰剂更易转为更低KDIGO风险类别(OR 1.69,95%CI 1.32-2.16)。
  • 司美格鲁肽组对比安慰剂更少转为更高KDIGO风险类别(OR 0.71,95%CI 0.59-0.86)。

临床怎么用

  • 对于2型糖尿病合并心血管疾病或高心血管风险患者,每周一次司美格鲁肽可降低肾脏疾病复合终点风险并改善KDIGO风险类别。
  • 基线KDIGO风险分层不影响司美格鲁肽对肾脏结局的治疗效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are recommended by Kidney Disease: Improving Global Outcomes (KDIGO) as risk-based treatment for hyperglycemia, weight management, and cardiovascular (CV) risk reduction in people with type 2 diabetes (T2D) and chronic kidney disease (CKD). The aim of this post hoc analysis was to assess treatment effects of once weekly semaglutide on kidney disease outcomes by KDIGO risk category and on changes in KDIGO risk category, compared with placebo. METHODS: Participants with T2D and established CV disease or at high CV risk treated with once weekly semaglutide or placebo in SUSTAIN 6 (NCT01720446) were stratified by baseline KDIGO risk category (low [n = 1596], moderate [n = 831], high [n = 445], very high [n = 366]). Treatment effect was analyzed for a kidney disease composite end point (macroalbuminuria, serum creatinine doubling and estimated glomerular filtration rate [eGFR] < 45 ml/min per 1.73 m2, kidney replacement therapy, or death due to kidney disease) from baseline to 2 years. RESULTS: The treatment effect of semaglutide versus placebo was consistent across KDIGO categories for the kidney disease composite end point (hazard ratio [95% confidence interval (CI)]: 0.35 [0.07-1.72], 0.42 [0.25-0.72], 0.87 [0.45-1.71], and 0.72 [0.42-1.23] for low, moderate, high, and very high risk categories, respectively; P interaction = 0.28). Participants receiving semaglutide were more likely to move to a lower KDIGO risk category (odds ratio: 1.69; 95% CI: [1.32-2.16]) and less likely to move to a higher KDIGO risk category versus placebo (odds ratio: 0.71; 95% CI: [0.59-0.86]). CONCLUSION: Once weekly semaglutide versus placebo reduced risks of kidney disease end points and improved risk categories irrespective of baseline KDIGO risk.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Tuttle KR, Bain SC, Bosch-Traberg H, et al. Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 Trial. Kidney Int Rep. 2024. PMID: 39081763. doi:10.1016/j.ekir.2024.04.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。